- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05322889
Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel) (PrevTel)
Prevention of Paclitaxel-induced Neuropathic Pain by Telmisartan in Patients With Planned Paclitaxel Chemotherapy Due to Ovarian or Breast Cancer (PrevTel)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Paclitaxel is a cytostatic drug that is widely used for the first-line treatment of breast- and ovarian cancer and causes neuropathic pain in up to 87% of treated patients Treating mice with telmisartan causes a strong reduction of PIPNP, thus indicating that telmisartan may be a promising pharmacological treatment option for PIPNP in patients. It is proposed that telmisartan reduces the inflammatory component of PIPNP.
Telmisartan has a good risk profile, low occurrence of side effects and is generally well tolerated in patients.These collective characteristics make it a suitable, already approved and appropriate substance for combination therapy with paclitaxel.
Therefore, telmisartan is a promising candidate to potentially prevent PIPNP in patients whose safety profile is well known due to preclinical and clinical trials for the indication of hypertension and coronary heart disease. Moreover, due to its mechanisms it might as well reduce symptoms of PIPNP sufficiently without severe side effects.
To validate these observations clinically, this phase IIa clinical trial will be conducted with breast and ovarian cancer patients requiring in-label paclitaxel-chemotherapy. The efficacy of a 12-week telmisartan treatment initiated before the first administration of paclitaxel to prevent PIPNP will be assessed.
Moreover, beside lipid profiles, quantitative sensoric testing of pain characteristics in focus on biomarker detection and development that may be useful for a precision medicine approach will be assessed.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Christin Jonetzko
- Phone Number: 00 49 69 6301 80231
- Email: christin.jonetzko@itmp.fraunhofer.de
Study Contact Backup
- Name: Tanja Rossmanith, PhD
- Email: tanja.rossmanith@itmp.fraunhofer.de
Study Locations
-
-
-
Frankfurt, Germany, 60590
- Recruiting
- Department of Haematology/Medical Onkology, University Hospital, Goethe-University Frankfurt
-
Contact:
- Martin Sebastian, MD
- Email: Martin.Sebastian@kgu.de
-
Principal Investigator:
- Martin Sebastian, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a diagnosis of ovarian or breast cancer who are clinically eligible for paclitaxel therapy and for whom paclitaxel chemotherapy is planned (with use of standard treatment) in clinical routine care.
- Female patients ≥ 18 years and ≤ 80 years
- The patient must have completed radiotherapy or surgery for central nervous system (CNS) metastases > 2 weeks prior to screening (SCR). Patients must be neurologically stable, having no new neurological deficits on clinical examination, and no new findings on CNS imaging as documented in clinical routine care. If patients require steroids for management of CNS metastases, they must have been on a stable dose of steroids for 2 weeks preceding SCR.
- Written informed consent obtained prior to the initiation of any protocol-required procedures
- Willingness to comply to study procedures and study protocol
Exclusion Criteria:
- Previously diagnosed or current peripheral neuropathic pain
- Other severe pain that might impair the assessment of neuropathic pain
- DN4 score ≥ 4
- Previous chemotherapy (incl. paclitaxel) within the last 5 years (treatment with cyclophosphamide and an anthracycline as part of an ongoing adjuvant or neo-adjuvant regimen is allowed)
- Current or planned combinational chemotherapy-regimens, e.g., with platinum-based drugs (Her2 antibodies are allowed; paclitaxel combination with trastuzumab +/- pertuzumab is allowed)
- All primary central nervous system (CNS) tumors or symptomatic CNS metastases that are neurologically unstable (Note: Only patients with controlled CNS metastases may participate in this trial)
- Previously reported intolerance to Angiotensin II (AT1) -receptor-blockers
- Hypotension (blood pressure < 110/70 mmHg; median from 3 measurements; start of measurement after patients has been seated for at least 5 minutes)
- Current intake of aliskiren, digoxin or Angiotensin-converting-enzyme (ACE)-inhibitors at baseline (BL) (treatment change from ACE-inhibitors to telmisartan is allowed, with treatment start of telmisartan at BL)
- Current intake of antidepressants (e.g., amitriptylin), antiepileptics (e.g., gabapentin, pregabalin, lamotrigine), duloxetine, glutamin, vitamin E
- Current intake of telmisartan at SCR
Insufficient hepatic or renal function at SCR:
- Serum creatinine ≥ 1.5 x upper limit of normal (ULN)
- Total bilirubin > 1.5 x ULN
- Glutamate-Oxalacetete-Transaminase/Glutamate-Pyruvate-Transaminase (GOT/GPT) ≥ 3 x ULN or >5 in case of documented liver metastasis
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)
- History of or current severe psychological illness or condition
- Uncontrolled coronary angina or symptomatic congestive heart failure (NYHA (New York Heart Association) Class III or IV)
- Patients with current malignant disease, other than that being treated in this study. Exceptions to this exclusion criterion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to SCR; completely resected basal cell and squamous cell skin cancers; and completely resected carcinoma in situ of any type
- Evidence of significant uncontrolled concomitant diseases or serious and/or uncontrolled diseases that are likely to interfere with the evaluation of the patient's safety and of the study outcome
- History of or evidence of current active Hepatitis B or C or Human Immunodeficiency Virus (HIV) infection with documentation not older than 8 weeks (due to blood sample processing for lipid profile analysis)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention with Telmisartan
Telmisartan (open), 80 mg daily p.o. (after run-in phase with 40 mg for 7 days). for 12 weeks |
12 weeks treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
efficacy of telmisartan to prevent new onset of Paclitaxel- induced peripheral neuropathic pain (PIPNP)
Time Frame: week 12
|
Proportion of patients without onset of PIPNP measured by median Quality of life questionaire (doleur neuropathic questionnaire) DN4, DN4 < 4
|
week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with new onset of PIPNP
Time Frame: Day 14
|
Douleur Neuropathique 4 (DN4) questionnaire (DN4 ≥ 4) higher score means more pain, minimum 0 to maximum 10 points
|
Day 14
|
Proportion of patients with new onset of PIPNP
Time Frame: Day 28
|
DN4 questionnaire (DN4 ≥ 4) higher score means more pain, minimum 0 to maximum 10 points
|
Day 28
|
Proportion of patients with new onset of PIPNP
Time Frame: Day 49
|
DN4 questionnaire (DN4 ≥ 4) higher score means more pain, minimum 0 to maximum 10 points
|
Day 49
|
Proportion of patients with new onset of PIPNP
Time Frame: Day 70
|
DN4 questionnaire DN4 ≥ 4
|
Day 70
|
Proportion of patients with new onset of PIPNP
Time Frame: Day 84
|
DN4 questionnaire DN4 ≥ 4 higher score means more pain, minimum 0 to maximum 10 points
|
Day 84
|
Change of pain intensity to baseline - Paindetect
Time Frame: Day 14
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 14
|
Change of pain intensity to baseline - Paindetect
Time Frame: Day 28
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 28
|
Change of pain intensity to baseline - Paindetect
Time Frame: Day 49
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 49
|
Change of pain intensity to baseline - Paindetect
Time Frame: Day 70
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 70
|
Change of pain intensity to baseline - Paindetect
Time Frame: Day 84
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 84
|
Change of pain intensity to baseline - VAS
Time Frame: Day 14
|
patient global pain visual analogue scale (VAS-Pain), minimum 0 to 10, higher score means more pain
|
Day 14
|
Change of pain intensity to baseline - VAS
Time Frame: Day 28
|
patient global pain visual analogue scale (VAS-Pain), minimum 0 to 10, higher score means more pain
|
Day 28
|
Change of pain intensity to baseline - VAS
Time Frame: Day 49
|
patient global pain visual analogue scale (VAS-Pain), minimum 0 to 10, higher score means more pain
|
Day 49
|
Change of pain intensity to baseline - VAS
Time Frame: Day 70
|
patient global pain visual analogue scale (VAS-Pain), minimum 0 to 10, higher score means more pain
|
Day 70
|
Change of pain intensity to baseline - VAS
Time Frame: Day 84
|
patient global pain visual analogue scale (VAS-Pain), minimum 0 to 10, higher score means more pain
|
Day 84
|
Change in pain pattern to baseline
Time Frame: Day 14
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 14
|
Change in pain pattern to baseline
Time Frame: Day 28
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 28
|
Change in pain pattern to baseline
Time Frame: Day 49
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 49
|
Change in pain pattern to baseline
Time Frame: Day 70
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 70
|
Change in pain pattern to baseline
Time Frame: Day 84
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 84
|
Change of pain quality to baseline
Time Frame: Day 14
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 14
|
Change of pain quality to baseline
Time Frame: Day 28
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 28
|
Change of pain quality to baseline
Time Frame: Day 49
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 49
|
Change of pain quality to baseline
Time Frame: Day 70
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 70
|
Change of pain quality to baseline
Time Frame: Day 84
|
PainDetect questionnaire, higher score means more pain, minimum 0 to 38 maximum
|
Day 84
|
Change in quality of life (QoL) to baseline
Time Frame: Day 14
|
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX questionnaire) - some items are reverse scored.
Subscale scores, total scores possible
|
Day 14
|
Change in quality of life (QoL) to baseline
Time Frame: Day 49
|
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX questionnaire) - some items are reverse scored.
Subscale scores, total scores possible
|
Day 49
|
Change in quality of life (QoL) to baseline
Time Frame: Day 28
|
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX questionnaire) - some items are reverse scored.
Subscale scores, total scores possible
|
Day 28
|
Change in quality of life (QoL) to baseline
Time Frame: Day 70
|
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX questionnaire) - some items are reverse scored.
Subscale scores, total scores possible
|
Day 70
|
Change in quality of life (QoL) to baseline
Time Frame: Day 84
|
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX questionnaire) - some items are reverse scored.
Subscale scores, total scores possible
|
Day 84
|
cumulative incidence of neuropathic pain
Time Frame: throughout study treatment - 12 weeks
|
documented by physician
|
throughout study treatment - 12 weeks
|
Quantification of the incidence of paclitaxel-associated acute pain syndrome (PAPS)
Time Frame: throughout study treatment - 12 weeks
|
documented by physician
|
throughout study treatment - 12 weeks
|
proportion of patients in need of PIPNP symptomatic therapy
Time Frame: throughout study treatment - 12 weeks
|
determined by treating physician - documented in case report form
|
throughout study treatment - 12 weeks
|
Assessment of frequency of adverse events
Time Frame: throughout study treatment - 12 weeks
|
determined by using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
throughout study treatment - 12 weeks
|
Assessment of severity of adverse events
Time Frame: throughout study treatment - 12 weeks
|
determined by using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
throughout study treatment - 12 weeks
|
Assessment relatedness of adverse events
Time Frame: throughout study treatment - 12 weeks
|
determined by using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
throughout study treatment - 12 weeks
|
Assessment of type of adverse events
Time Frame: throughout study treatment - 12 weeks
|
determined by using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
throughout study treatment - 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Martin Sebastian, MD, Department of Haematology/Medical Onkology, University Hospital, Goethe-University Frankfurt
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMP-0315-2018
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathic Pain
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
University Malaysia SarawakPersatuan Diabetes MalaysiaCompletedNeuropathic Pain, Nociceptive PainMalaysia
-
University Hospital, Clermont-FerrandRecruitingPeripheral Neuropathic PainFrance
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Hospices Civils de LyonCompletedPharmacoresistant Neuropathic PainFrance
-
Yuhan CorporationCompletedPeripheral Neuropathic PainKorea, Republic of
-
University Hospital, Clermont-FerrandCompletedNeuropathic Pain RebelFrance
-
University Hospital, Strasbourg, FranceTerminatedPostthoracotomy Pain | Postthoracoscopy Neuropathic PainFrance
-
AstraZenecaCompletedNociceptive Pain | Peripheral Neuropathic PainUnited Kingdom
Clinical Trials on Telmisartan tablets
-
Kyoto Prefectural University of MedicineTerminatedMyocardial Ischemia | Hypertension | Angina Pectoris | Acute Coronary Syndrome | Acute Myocardial InfarctionJapan
-
TakedaCompletedEssential Hypertension Complicated by Type 2 Diabetes MellitusJapan
-
Emory UniversityNational Institute on Aging (NIA)Completed
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedDiabetic NephropathiesJapan